aTYR PHARMA INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
aTYR PHARMA INC (ATYR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $10.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-05
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $10.00K.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.00K, a 98.75% decline from fiscal 2021.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $80.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $10.00K 10-K · filed 2026-03-05 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 |
| 2022-12-31 | $1.00K 10-K · filed 2025-03-13 |
| 2021-12-31 | $80.00K 10-K · filed 2024-03-14 |
| 2020-12-31 | $0.00 10-K · filed 2023-03-14 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-15 |
| 2018-12-31 | $6.00K 10-K · filed 2021-03-24 |
| 2017-12-31 | $300.00K 10-K · filed 2020-03-26 |
| 2016-12-31 | $34.00K 10-K · filed 2019-03-26 |
| 2015-12-31 | $1.90M 10-K · filed 2018-03-20 |
| 2014-12-31 | $400.00K 10-K · filed 2017-03-16 |
| 2013-12-31 | $47.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |